Aberdeen Group
RCUS icon

Aberdeen Group’s Arcus Biosciences RCUS Stock Holding History

Aberdeen Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1M Sell
650,712
-119,075
-15% -$2.94M 0.03% 447
2026
Q1 		$16.6M Buy
769,787
+385,186
+100% +$8.32M 0.03% 473
2025
Q4 		$9.17M Buy
384,601
+52,930
+16% +$1.08M 0.01% 623
2025
Q3 		$4.42M Buy
+331,671
New +$3.45M 0.01% 715

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Aberdeen Group's RCUS Position: Q2 2026 in Review

Aberdeen Group reduced its Arcus Biosciences (RCUS) stake by 15% in Q2 2026, selling an estimated $2.94M and leaving 650,712 shares worth $20.1M. The position accounts for 0.03% of the portfolio, ranked #447.

Aberdeen Group first reported a position in RCUS in Q3 2025 and has held it in 4 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Aberdeen Group held 650,712 shares of Arcus Biosciences worth $20.1M as of Q2 2026.
  • Aberdeen Group sold 119,075 Arcus Biosciences shares in Q2 2026, an estimated $2.94M.
  • Arcus Biosciences made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #447 holding.
  • Aberdeen Group first reported a position in Arcus Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.